Francis Lo of Adaptive Biotechnologies Sells Shares Worth $695,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Executive Stock Sale: Francis Lo, Chief People Officer of Adaptive Biotechnologies, sold 39,741 shares of common stock for approximately $695,000, indicating a strategic liquidity management move, despite a 13.56% reduction in direct holdings to 250,934 shares.
- Options Exercise and Sale: The transaction involved exercising 19,521 options and selling shares, suggesting that Lo's sale was a liquidity measure tied to options compensation rather than a decrease in long-term holdings, reflecting ongoing confidence in the company's future.
- Holding Structure Analysis: Post-transaction, Lo retains 483,489 stock options, not all of which are vested, indicating continued potential for equity participation and maintaining significant influence over the company’s direction.
- Company Performance Highlights: Adaptive Biotechnologies reported $70.9 million in revenue for the first quarter, representing a robust 35% year-over-year increase, further supporting the upward momentum of its stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.730
Low
20.00
Averages
20.86
High
22.00
Current: 18.730
Low
20.00
Averages
20.86
High
22.00
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Francis Lo Sells Shares of Adaptive Biotechnologies
- Transaction Overview: Chief People Officer Francis Lo sold 39,741 shares of Common Stock on June 4, 2026, for approximately $695,000 at a weighted average price of $17.49 per share, reducing his direct holdings to 250,934 shares, which indicates his ongoing confidence in the company's stock.
- Options Exercise Context: The sale involved the exercise of 19,521 stock options, with all shares sold being directly held, and the transaction was part of a pre-arranged Rule 10b5-1 trading plan established in September 2025, indicating it was non-discretionary and mitigating insider trading concerns.
- Ownership Analysis: Despite the sale, Lo retains a significant equity stake with 250,934 shares directly held and an additional 2,500 shares indirectly through his spouse, along with 483,489 stock options, demonstrating his continued investment confidence in the company's future.
- Company Performance: Adaptive Biotechnologies reported revenue of $70.9 million for Q1 2026, reflecting a robust 35% year-over-year increase, showcasing strong growth momentum in the immune-driven precision medicine sector, and while Lo's stock sale did not trigger market volatility, the company's fundamentals remain solid.
See More
Francis Lo of Adaptive Biotechnologies Sells Shares Worth $695,000
- Executive Stock Sale: Francis Lo, Chief People Officer of Adaptive Biotechnologies, sold 39,741 shares of common stock for approximately $695,000, indicating a strategic liquidity management move, despite a 13.56% reduction in direct holdings to 250,934 shares.
- Options Exercise and Sale: The transaction involved exercising 19,521 options and selling shares, suggesting that Lo's sale was a liquidity measure tied to options compensation rather than a decrease in long-term holdings, reflecting ongoing confidence in the company's future.
- Holding Structure Analysis: Post-transaction, Lo retains 483,489 stock options, not all of which are vested, indicating continued potential for equity participation and maintaining significant influence over the company’s direction.
- Company Performance Highlights: Adaptive Biotechnologies reported $70.9 million in revenue for the first quarter, representing a robust 35% year-over-year increase, further supporting the upward momentum of its stock price.
See More
Adaptive Biotechnologies Executive Sells Nearly 40,000 Shares
- Executive Stock Sale: Francis Lo, Chief People Officer of Adaptive Biotechnologies, sold 39,741 shares of common stock for approximately $695,000, indicating a liquidity management strategy; despite a 13.56% decrease in direct holdings to 250,934 shares, he retains 483,489 stock options, ensuring future equity participation potential.
- Transaction Context: The sale involved exercising 19,521 options and selling shares, suggesting a liquidity move tied to options-based compensation rather than a reduction in long-term exposure, and it was executed under a pre-arranged Rule 10b5-1 trading plan established in September 2025 to avoid insider trading accusations.
- Company Financials: Adaptive Biotechnologies has a market capitalization of $2.82 billion and reported $295.41 million in revenue over the last twelve months, with a net income of -$49.68 million; however, its stock price has increased by 69.07% over the past year, reflecting market confidence in its business outlook.
- Investor Considerations: While Lo's stock sale is routine and he maintains significant equity, analysts note that Adaptive Biotechnologies was not included in the current list of top investment stocks, prompting investors to carefully assess its market performance and future potential before making purchases.
See More
Adaptive Biotechnologies Shares Surge 9.7% Amid Strong Volume
- Stock Price Surge: Adaptive Biotechnologies shares rose 9.7% to close at $18.73, driven by notable trading volume that exceeded typical levels, indicating increased investor confidence and potential for future growth.
- Strong Financial Performance: The company reported robust first-quarter results for 2026, with expected revenues of $67.24 million, reflecting a 14.2% year-over-year increase, showcasing its ongoing growth in immune profiling diagnostics and drug discovery.
- Upward Earnings Revision: Although a quarterly loss of $0.13 per share is anticipated, the consensus EPS estimate has been revised 3.6% higher, which typically correlates with stock price appreciation, indicating market optimism about the company's future performance.
- Industry Position: Adaptive Biotechnologies holds a Zacks Rank of #3 (Hold) within the Zacks Medical - Biomedical and Genetics industry, demonstrating its stable position despite competitive pressures from peers like Prothena.
See More
Adaptive Biotechnologies Showcases clonoSEQ Test at ASCO and EHA Meetings
- Clinical Presentation Volume: Adaptive Biotechnologies will showcase its clonoSEQ® test in 33 presentations at ASCO and EHA, including one plenary session and 14 oral presentations, highlighting the test's significance and broad application in modern hematologic oncology.
- Multiple Myeloma Research: The clonoSEQ test demonstrates depth and durability of response to novel therapies in the inMMyCAR trial and MONUMENTAL-3 study, with final analysis showing higher rates of sustained MRD negativity in patients treated with the quadruplet regimen, thereby enhancing evidence-based treatment decisions.
- Chronic Lymphocytic Leukemia Applications: In studies like BOVen-∆MRD400 and venetoSTOP, MRD measurement is incorporated into therapy duration and discontinuation decisions, indicating that personalized treatment can lead to durable treatment-free remissions, significantly improving patient quality of life.
- Global Impact Expansion: New data presented at EHA further supports the application of clonoSEQ in MRD assessment, with increasing biopharmaceutical industry investment in MRD-guided treatment driving significant growth in clonoSEQ's global influence and market demand.
See More
Harvest Investment Fully Exits Adaptive Biotechnologies Stake
- Complete Exit: Harvest Investment Services sold its entire stake of 356,114 shares in Adaptive Biotechnologies during Q1 2026, valued at approximately $5.67 million, indicating a potential loss of confidence that may impact market perception of Adaptive.
- Asset Reallocation: Following this transaction, Adaptive Biotechnologies now represents 0% of Harvest's 13F reportable assets, with its top five holdings including NASDAQ: LMBS at 8.16%, reflecting a strategic shift in Harvest's investment focus.
- Market Performance Comparison: As of May 26, 2026, Adaptive Biotechnologies shares were priced at $114.09, up 57.78% year-over-year, outperforming the S&P 500 by 28.3 percentage points, highlighting its strong position in the biotechnology sector.
- Future Growth Potential: Although Harvest's exit may be a short-term decision, Adaptive's MRD testing sales surged by 53% year-over-year, indicating significant growth potential in cancer diagnostics that could attract renewed investor interest.
See More
Francis Lo Sells Shares of Adaptive Biotechnologies
- Transaction Overview: Chief People Officer Francis Lo sold 39,741 shares of Common Stock on June 4, 2026, for approximately $695,000 at a weighted average price of $17.49 per share, reducing his direct holdings to 250,934 shares, which indicates his ongoing confidence in the company's stock.
- Options Exercise Context: The sale involved the exercise of 19,521 stock options, with all shares sold being directly held, and the transaction was part of a pre-arranged Rule 10b5-1 trading plan established in September 2025, indicating it was non-discretionary and mitigating insider trading concerns.
- Ownership Analysis: Despite the sale, Lo retains a significant equity stake with 250,934 shares directly held and an additional 2,500 shares indirectly through his spouse, along with 483,489 stock options, demonstrating his continued investment confidence in the company's future.
- Company Performance: Adaptive Biotechnologies reported revenue of $70.9 million for Q1 2026, reflecting a robust 35% year-over-year increase, showcasing strong growth momentum in the immune-driven precision medicine sector, and while Lo's stock sale did not trigger market volatility, the company's fundamentals remain solid.
See More
Francis Lo of Adaptive Biotechnologies Sells Shares Worth $695,000
- Executive Stock Sale: Francis Lo, Chief People Officer of Adaptive Biotechnologies, sold 39,741 shares of common stock for approximately $695,000, indicating a strategic liquidity management move, despite a 13.56% reduction in direct holdings to 250,934 shares.
- Options Exercise and Sale: The transaction involved exercising 19,521 options and selling shares, suggesting that Lo's sale was a liquidity measure tied to options compensation rather than a decrease in long-term holdings, reflecting ongoing confidence in the company's future.
- Holding Structure Analysis: Post-transaction, Lo retains 483,489 stock options, not all of which are vested, indicating continued potential for equity participation and maintaining significant influence over the company’s direction.
- Company Performance Highlights: Adaptive Biotechnologies reported $70.9 million in revenue for the first quarter, representing a robust 35% year-over-year increase, further supporting the upward momentum of its stock price.
See More
Adaptive Biotechnologies Executive Sells Nearly 40,000 Shares
- Executive Stock Sale: Francis Lo, Chief People Officer of Adaptive Biotechnologies, sold 39,741 shares of common stock for approximately $695,000, indicating a liquidity management strategy; despite a 13.56% decrease in direct holdings to 250,934 shares, he retains 483,489 stock options, ensuring future equity participation potential.
- Transaction Context: The sale involved exercising 19,521 options and selling shares, suggesting a liquidity move tied to options-based compensation rather than a reduction in long-term exposure, and it was executed under a pre-arranged Rule 10b5-1 trading plan established in September 2025 to avoid insider trading accusations.
- Company Financials: Adaptive Biotechnologies has a market capitalization of $2.82 billion and reported $295.41 million in revenue over the last twelve months, with a net income of -$49.68 million; however, its stock price has increased by 69.07% over the past year, reflecting market confidence in its business outlook.
- Investor Considerations: While Lo's stock sale is routine and he maintains significant equity, analysts note that Adaptive Biotechnologies was not included in the current list of top investment stocks, prompting investors to carefully assess its market performance and future potential before making purchases.
See More
Adaptive Biotechnologies Shares Surge 9.7% Amid Strong Volume
- Stock Price Surge: Adaptive Biotechnologies shares rose 9.7% to close at $18.73, driven by notable trading volume that exceeded typical levels, indicating increased investor confidence and potential for future growth.
- Strong Financial Performance: The company reported robust first-quarter results for 2026, with expected revenues of $67.24 million, reflecting a 14.2% year-over-year increase, showcasing its ongoing growth in immune profiling diagnostics and drug discovery.
- Upward Earnings Revision: Although a quarterly loss of $0.13 per share is anticipated, the consensus EPS estimate has been revised 3.6% higher, which typically correlates with stock price appreciation, indicating market optimism about the company's future performance.
- Industry Position: Adaptive Biotechnologies holds a Zacks Rank of #3 (Hold) within the Zacks Medical - Biomedical and Genetics industry, demonstrating its stable position despite competitive pressures from peers like Prothena.
See More
Adaptive Biotechnologies Showcases clonoSEQ Test at ASCO and EHA Meetings
- Clinical Presentation Volume: Adaptive Biotechnologies will showcase its clonoSEQ® test in 33 presentations at ASCO and EHA, including one plenary session and 14 oral presentations, highlighting the test's significance and broad application in modern hematologic oncology.
- Multiple Myeloma Research: The clonoSEQ test demonstrates depth and durability of response to novel therapies in the inMMyCAR trial and MONUMENTAL-3 study, with final analysis showing higher rates of sustained MRD negativity in patients treated with the quadruplet regimen, thereby enhancing evidence-based treatment decisions.
- Chronic Lymphocytic Leukemia Applications: In studies like BOVen-∆MRD400 and venetoSTOP, MRD measurement is incorporated into therapy duration and discontinuation decisions, indicating that personalized treatment can lead to durable treatment-free remissions, significantly improving patient quality of life.
- Global Impact Expansion: New data presented at EHA further supports the application of clonoSEQ in MRD assessment, with increasing biopharmaceutical industry investment in MRD-guided treatment driving significant growth in clonoSEQ's global influence and market demand.
See More
Harvest Investment Fully Exits Adaptive Biotechnologies Stake
- Complete Exit: Harvest Investment Services sold its entire stake of 356,114 shares in Adaptive Biotechnologies during Q1 2026, valued at approximately $5.67 million, indicating a potential loss of confidence that may impact market perception of Adaptive.
- Asset Reallocation: Following this transaction, Adaptive Biotechnologies now represents 0% of Harvest's 13F reportable assets, with its top five holdings including NASDAQ: LMBS at 8.16%, reflecting a strategic shift in Harvest's investment focus.
- Market Performance Comparison: As of May 26, 2026, Adaptive Biotechnologies shares were priced at $114.09, up 57.78% year-over-year, outperforming the S&P 500 by 28.3 percentage points, highlighting its strong position in the biotechnology sector.
- Future Growth Potential: Although Harvest's exit may be a short-term decision, Adaptive's MRD testing sales surged by 53% year-over-year, indicating significant growth potential in cancer diagnostics that could attract renewed investor interest.
See More
